India DCGI Urges Cancer Drugs Be Included In Price Cap System
This article was originally published in PharmAsia News
The Drug Controller General of India is pushing to have cancer drugs added to the country's system of price caps on pharmaceuticals. DCGI Surinder Singh said cancer drugs have become too expensive for those who need them, partly because five multinational companies have a near monopoly on that drug sector. He said Eli Lilly, GlaxoSmithKline, Pfizer, Roche and Sanofi-Aventis control the cancer category of drugs. Singh said he has recommended inclusion of cancer drugs in the National Pharmaceutical Pricing Authority, but it would be up to the department of pharmaceuticals to do so. (Click here for more
You may also be interested in...
Infographic timeline looks at key moments in the history of vaccine development, from the first vaccine against smallpox to the polio field trial involving 1.8 million children to the flurry of vaccines created by ‘the scientist who saved more lives than all other scientists combined.’
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.